His areas of expertise include biological and pharmacological aspects of mood, anxiety, and behavioral disorders in children, as well as classification of psychopathology across the lifespan. This expertise is reflected in more than 300 peer-reviewed papers. Currently, his research group is examining the degree to which mood and anxiety disorders in children and adolescents are associated with underlying abnormalities in the amygdala, prefrontal cortex, and associated brain regions. Dr. Pine has served as the Chair of the Psychopharmacologic Drug Advisory Committee for the Food and Drug Administration and Chair of the Child and Adolescent Diagnosis Group for the DSM-5 Task Force. He has received many awards, including the Joel Elkes Award from the American College of Neuropsychopharmacology, the Blanche Ittelson Award from the American Psychiatric Association, and the Ruane Prize from the Brain & Behavior Research Foundation.